Changes between Initial Version and Version 1 of NIAID2023


Ignore:
Timestamp:
May 11, 2023, 2:24:37 PM (2 years ago)
Author:
Scooter Morris
Comment:

--

Legend:

Unmodified
Added
Removed
Modified
  • NIAID2023

    v1 v1  
     1= NIAID Guidehouse/MSC contract May 1, 2022 - Feb 28, 2023 =
     2
     31. General ChimeraX improvements to support NIAID.
     4 a. Provide support for an NIAID internal app store
     5 b. Specific improvements to assist NIAID personnel to transition away from the unsupported legacy Chimera program, e.g.:
     6   i. More GUIs (notably, copy/combine, 2D labels)
     7 c. Investigate and improve ChimeraX usability for very wide displays and touch screens
     8   i. Specific focus on the BioViz lab wall display
     9 d. Work with Enduvo to improve exporting ChimeraX scenes in various formats to their environment.
     102. Support the NIH 3D pipeline development, including any changes to ChimeraX to support ongoing development.
     11 a. Put presets on github
     12  i. Improve presets documentation
     13 b. Share code interacting with ChimeraX and NIH3D on github
     14 c. Continuing support for NIH3D as needed
     153. Extend virtual reality support
     16 a. Investigate molecular viewer for standalone headsets such as Quest 2.
     17 b. Investigate use of pass-through video with the Quest Pro for multi-person sessions.
     18 c. Implement a VR ergonomic toolbar and Model panel user interface.
     19 d. Migrate ChimeraX from SteamVR to OpenXR, the current API standard for cross-platform virtual reality.
     204. Explore pedagogical benefits of ChimeraX in VR vs. flat screen
     21 a. Develop a single web page describing ChimeraX VR capabilities and link to existing tutorials, how-tos, equipment advice.
     22 b. Describe use cases where VR is advantageous.
     23 c. Collaborate with the University of Indiana (Katy Borner), UCSF, and NIAID to conduct a task analysis comparing VR vs. flat screen for understanding biological macromolecules
     245. Medical Images
     25 a. Improve DICOM reader by including more data types such as segmentations, and making it more robust by testing against the NCI TCIA repository.
     26 b. Add ability to “fetch” studies from TCIA
     27 c. Add support for NifTI format
     28 d. Add support for NRRD files
     29 e. Improve VR experience for medical images
     30  i. Easier manipulation of windowing and leveling, especially for complex curves
     31 f. General usability improvements for using ChimeraX with medical images driven by TCIA data
     326. Outreach
     33 a. Instructional material and tools documentation.
     34  i. Detailed instructions for all features shall be provided in a user manual.
     35  ii.Written user guides and tutorials shall be available as HTML pages.
     36  iii. Create videos demonstrating new capabilities.
     37  iv. Present webinar and workshop tutorials to train users on existing and new capabilities.
     38 b. Create video tutorials for how to use multi-person VR.
     39Attendance at meetings or workshops as required by NIAID
     407. Administration
     41 a. Submit monthly written reports of accomplishments
     42
     43
     44== 5/11/2023 ==
     45
     46Phil, Scooter, Zach, Renata, Greg, Tom, Eric. Kristin, Mehgan
     47
     48Mehgan: Dmitry at Seattle doing VR work including with clinical applications
     49
     50Zach: Nifty & NRRD support. TCIA lists ChimeraX as an analysis tool -- Federick labs still sending bugs (lots of interest)
     51
     52Eric: pseudo-bond error (pseudo bonds don't always connect to the ribbon). Phil is going to review ticket again and see how important it is
     53
     54Elaine: introduction
     55
     56Greg: introduction, work on small molecules
     57
     58Tom: VR standalone, Quest Pro broken, Quest Pro very effective. Discussion about the resolution of the camera in the Quest Pro
     59
     60Phil: Confusion about Mac install (does Universal installer install M1?)
     61
     62Kristin: High priority NIH3D issues
     63
     64* No color modules should always use materials, not vertex coloring (small molecules use vertex colors). Possibly the GLTF writer could potentially switch from vertex coloring to material coloring if the color is all the same
     65* Resolution of surface models is inconsistent between chimera and chimerax. Chimera is higher resolution is higher resolution.
     66* Issue with shading and 3D printing (possibly drop normal vectors)